A novel cell culture system modeling the SARS-CoV-2 life cycle
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the global pandemic of COVID-19. SARS-CoV-2 is classified as a biosafety level-3 (BSL-3) agent, impeding the basic research into its biology and the development of effective antivirals. Here, we developed a biosafety level-2 (BSL-2) cell culture system for production of transcription and replication-competent SARS-CoV-2 virus-like-particles (trVLP). This trVLP expresses a reporter gene (GFP) replacing viral nucleocapsid gene (N), which is required for viral genome packaging and virion assembly (SARS-CoV-2 GFP/ΔN trVLP). The complete viral life cycle can be achieved and exclusively confined in the cells ectopically expressing SARS-CoV or SARS-CoV-2 N proteins, but not MERS-CoV N. Genetic recombination of N supplied in trans into viral genome was not detected, as evidenced by sequence analysis after one-month serial passages in the N-expressing cells. Moreover, intein-mediated protein trans-splicing approach was utilized to split the viral N gene into two independent vectors, and the ligated viral N protein could function in trans to recapitulate entire viral life cycle, further securing the biosafety of this cell culture model. Based on this BSL-2 SARS-CoV-2 cell culture model, we developed a 96-well format high throughput screening for antivirals discovery. We identified salinomycin, tubeimoside I, monensin sodium, lycorine chloride and nigericin sodium as potent antivirals against SARS-CoV-2 infection. Collectively, we developed a convenient and efficient SARS-CoV-2 reverse genetics tool to dissect the virus life cycle under a BSL-2 condition. This powerful tool should accelerate our understanding of SARS-CoV-2 biology and its antiviral development.
Article activity feed
-
-
SciScore for 10.1101/2020.12.13.422469: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication Contamination: All cell lines were tested negative for mycoplasma. Table 2: Resources
Antibodies Sentences Resources IFN-β, neutralizing antibody and drug treatment: To assess the antiviral efficacies of the materials, 1×104 Caco-2-N cells were seeded into 96-well plates. IFN-βsuggested: NoneThe blots were exposed to primary antibodies anti-N (05-0154, AbMax), S (40589-T62, Sino Biological), β-Tubulin (CW0098, CWBIO), Flag (F7425, Sigma), ACE2 (10108-T24, Sino Biological) in 5% nonfat milk in 1×PBS containing 0.1% … SciScore for 10.1101/2020.12.13.422469: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication Contamination: All cell lines were tested negative for mycoplasma. Table 2: Resources
Antibodies Sentences Resources IFN-β, neutralizing antibody and drug treatment: To assess the antiviral efficacies of the materials, 1×104 Caco-2-N cells were seeded into 96-well plates. IFN-βsuggested: NoneThe blots were exposed to primary antibodies anti-N (05-0154, AbMax), S (40589-T62, Sino Biological), β-Tubulin (CW0098, CWBIO), Flag (F7425, Sigma), ACE2 (10108-T24, Sino Biological) in 5% nonfat milk in 1×PBS containing 0.1% Tween 20 for 2 h. anti-Nsuggested: Noneβ-Tubulinsuggested: (CWBio Cat# CW0098, RRID:AB_2814800)CW0098 , CWBIO) , Flag ( F7425suggested: NoneACE2suggested: (Enzo Life Sciences Cat# ALX-804-722-C100, RRID:AB_11180102)Cells were fixed with 4% paraformaldehyde in PBS, permeablized with 0.2% Triton X-100, and incubated with the rabbit polyclonal antibody against SARS-CoV nucleocapsid protein (Rockland, 200-401-A50, 1μg/ml) at 4 °C overnight. SARS-CoV nucleocapsid proteinsuggested: (Creative Diagnostics Cat# DMAB8869, RRID:AB_2392503)After three washes, cells were incubated with the secondary goat anti-rabbit antibody conjugated with Alexa Fluor 555 (Thermo #A32732, 2 μg/ml) for 2 h at room temperature, followed by staining with 4’,6-diamidino-2-phenylindole (DAPI). anti-rabbitsuggested: (Thermo Fisher Scientific Cat# A32732, RRID:AB_2633281)Experimental Models: Cell Lines Sentences Resources Cell culture: HEK293T, Vero, Vero E6, A549 and Caco-2 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) (Gibco, China) supplemented with 10% (vol/vol HEK293Tsuggested: NoneVero E6suggested: NoneA549suggested: NoneCaco-2suggested: NoneTwenty micrograms of viral RNA and 20μg N mRNA were mixed and added to a 4-mm cuvette containing 0.4 mL of Caco-2-N cells (8×106) in Opti-MEM. Caco-2-Nsuggested: NoneAntiviral screening: Twelve hours prior to infection for the antiviral screening 5 × 104 Caco-2-Nint cells were seeded in 96 well plates. Caco-2-Nintsuggested: NoneSoftware and Algorithms Sentences Resources Heatmaps were drawn by using R package “pheatmap” (https://www.r-project.org). https://www.r-project.orgsuggested: (R Project for Statistical Computing, RRID:SCR_001905)To quantify the junction-reads from subgenomic RNAs, the STAR2.7.5c was used for reads mapping. STAR2.7.5csuggested: NoneThe 50% inhibitory concentrations (IC50; compound concentration required to inhibit viral replication by 50% reduction of GFP positive cells) were determined using logarithmic interpolation using GraphPad Prism software version 7.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Fixed cells were resuspended in PBS and analyzed by LSRFortessa SORP (BD Biosciences) and FlowJo software. FlowJosuggested: (FlowJo, RRID:SCR_008520)RNA-seq dataset generated here can be found in the aforementioned NCBI Gene Expression Omnibus ( Gene Expression Omnibussuggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-